AR128330A1 - Inductores químicos de degradación conjugados con anticuerpo y métodos de estos - Google Patents
Inductores químicos de degradación conjugados con anticuerpo y métodos de estosInfo
- Publication number
- AR128330A1 AR128330A1 ARP230100152A ARP230100152A AR128330A1 AR 128330 A1 AR128330 A1 AR 128330A1 AR P230100152 A ARP230100152 A AR P230100152A AR P230100152 A ARP230100152 A AR P230100152A AR 128330 A1 AR128330 A1 AR 128330A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- formula
- remainder
- group
- Prior art date
Links
- 238000002144 chemical decomposition reaction Methods 0.000 title abstract 2
- 239000000411 inducer Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303447P | 2022-01-26 | 2022-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128330A1 true AR128330A1 (es) | 2024-04-17 |
Family
ID=85477901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100152A AR128330A1 (es) | 2022-01-26 | 2023-01-24 | Inductores químicos de degradación conjugados con anticuerpo y métodos de estos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250064968A1 (enExample) |
| EP (1) | EP4469090A1 (enExample) |
| JP (1) | JP2025506357A (enExample) |
| CN (1) | CN118591393A (enExample) |
| AR (1) | AR128330A1 (enExample) |
| TW (1) | TW202340146A (enExample) |
| WO (1) | WO2023147328A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026090411A1 (en) * | 2024-10-23 | 2026-04-30 | Prelude Therapeutics Incorporated | Brm and brg1 targeting compounds and associated methods of use |
| WO2026145631A1 (zh) * | 2024-12-31 | 2026-07-09 | 上海复宏汉霖生物技术股份有限公司 | 一种配体-药物偶联物及制备方法和应用 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5091542A (en) * | 1990-03-09 | 1992-02-25 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
| US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6319688B1 (en) | 1997-04-28 | 2001-11-20 | Smithkline Beecham Corporation | Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1) |
| US20030060612A1 (en) | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US20020187472A1 (en) | 2001-03-09 | 2002-12-12 | Preeti Lal | Steap-related protein |
| US20030064397A1 (en) | 1998-05-22 | 2003-04-03 | Incyte Genomics, Inc. | Transmembrane protein differentially expressed in prostate and lung tumors |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| AU2001243142A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| WO2001072962A2 (en) | 2000-03-24 | 2001-10-04 | Fahri Saatcioglu | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| AU2001253140A1 (en) | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| EP1445318A2 (en) | 2000-08-24 | 2004-08-11 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| CA2446788A1 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| MXPA03011979A (es) | 2001-06-18 | 2005-04-08 | Eos Biotechnology Inc | Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario. |
| WO2003022995A2 (en) | 2001-09-06 | 2003-03-20 | Agensys, Inc. | Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| EP1476120B1 (en) | 2002-02-21 | 2010-09-29 | Duke University | Treatment methods using anti-cd22 antibodies |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| MXPA04009728A (es) | 2002-04-05 | 2005-06-08 | Agenysys Inc | Acido nucleico y proteina correspondiente titulada 98p4b6 en el tratamiento y deteccion del cancer. |
| WO2003104270A2 (en) | 2002-06-06 | 2003-12-18 | Ingenium Pharmaceuticals Ag | Dudulin 2 genes, expression products, non-human animal model: uses in human hematological disease |
| JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
| KR20050048615A (ko) | 2002-08-19 | 2005-05-24 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
| AU2002951346A0 (en) | 2002-09-05 | 2002-09-26 | Garvan Institute Of Medical Research | Diagnosis of ovarian cancer |
| JP2006501849A (ja) | 2002-10-04 | 2006-01-19 | ヴァン アンデル リサーチ インスティチュート | 腎腫瘍の分子サブ分類および新規診断マーカーの発見 |
| EP1583820A4 (en) | 2003-01-14 | 2007-07-18 | Bristol Myers Squibb Co | ASSOCIATED POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB WAY |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| JP2010519310A (ja) * | 2007-02-21 | 2010-06-03 | メダレックス インコーポレイテッド | 単一のアミノ酸を有する化学リンカーおよびその複合体 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| AU2009270988A1 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| WO2013017705A1 (es) | 2011-08-03 | 2013-02-07 | Salvador Moreno Rufino Baltasar | Sistema de panel para construccion con retroiluminacion a base de diodos electroluminosos |
| JP6104257B2 (ja) | 2011-10-14 | 2017-03-29 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンおよびそのコンジュゲート |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| PE20150025A1 (es) | 2012-05-21 | 2015-02-09 | Genentech Inc | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| KR20210132742A (ko) | 2012-12-21 | 2021-11-04 | 알트루바이오 인코퍼레이티드 | 친수성 자기-희생 링커 및 그것의 포합체 |
| BR112016002829A2 (pt) | 2013-08-12 | 2017-09-19 | Genentech Inc | Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi |
| BR112016012410A2 (pt) | 2013-12-16 | 2017-09-26 | Genentech Inc | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica |
| BR112016014126B1 (pt) | 2013-12-16 | 2023-02-14 | Medimmune Limited | Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos |
| UA118113C2 (uk) | 2013-12-16 | 2018-11-26 | Дженентек, Інк. | Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| EP3167887B1 (en) | 2014-07-07 | 2021-03-24 | Chen, Kuenfeng | Aryl amine substituted quinoxaline used as anticancer drugs |
| WO2016025752A1 (en) * | 2014-08-14 | 2016-02-18 | Prolynx Llc | Reagents for thiol conjugation and conjugates formed therefrom |
| JP6779876B2 (ja) | 2014-11-19 | 2020-11-04 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| AU2018288029B2 (en) * | 2017-06-19 | 2021-12-23 | Systimmune, Inc. | Antibody-drug conjugate having acidic self-stabilization junction |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| JP7502425B2 (ja) | 2019-10-01 | 2024-06-18 | アルヴィナス・オペレーションズ・インコーポレイテッド | Ｂｒｍ標的化化合物および関連使用方法 |
| JP7508578B2 (ja) | 2020-04-06 | 2024-07-01 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| IL299860A (en) * | 2020-07-21 | 2023-03-01 | Genentech Inc | Antibody-conjugated chemical factors for the discharge of BRM and their methods |
-
2023
- 2023-01-24 AR ARP230100152A patent/AR128330A1/es unknown
- 2023-01-25 JP JP2024544690A patent/JP2025506357A/ja active Pending
- 2023-01-25 WO PCT/US2023/061216 patent/WO2023147328A1/en not_active Ceased
- 2023-01-25 EP EP23709291.1A patent/EP4469090A1/en active Pending
- 2023-01-25 CN CN202380018416.3A patent/CN118591393A/zh active Pending
- 2023-01-30 TW TW112103149A patent/TW202340146A/zh unknown
-
2024
- 2024-07-25 US US18/784,386 patent/US20250064968A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4469090A1 (en) | 2024-12-04 |
| WO2023147328A1 (en) | 2023-08-03 |
| TW202340146A (zh) | 2023-10-16 |
| JP2025506357A (ja) | 2025-03-11 |
| US20250064968A1 (en) | 2025-02-27 |
| CN118591393A (zh) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003648A1 (es) | Conjugados de una molécula de unión celular con análogos de camptotecina | |
| CL2024001450A1 (es) | Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este | |
| ES2811301T3 (es) | Hidrogeles reticulados por química clic y métodos de uso | |
| PE20251755A1 (es) | Inhibidores de pcsk9 y metodos de uso de estos | |
| PE20231104A1 (es) | Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos | |
| EA202092176A1 (ru) | 177Lu-DOTA-HYNIC-iPSMA В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО РАДИОФАРМАЦЕВТИЧЕСКОГО СРЕДСТВА, НАЦЕЛЕННОГО НА ПРОСТАТИЧЕСКИЙ СПЕЦИФИЧЕСКИЙ МЕМБРАННЫЙ АНТИГЕН | |
| MX2022000037A (es) | Enlazadores hidrofilicos para conjugados de peptidos multivalentes. | |
| ES2624704T3 (es) | Resinas epoxídicas con alta estabilidad térmica y tenacidad | |
| ECSP077183A (es) | Derivados de la n-(1-bencil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil)benzamida y los compuestos relacionados como inhibidores de la proteína de quiinesina del huso (ksp) para el tratamiento del cáncer | |
| AR069495A1 (es) | Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis) | |
| EA201490709A1 (ru) | Адъювантное соединение | |
| JP2013520986A5 (enExample) | ||
| PE20221006A1 (es) | Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" | |
| RU2016110576A (ru) | Бактериальная вакцина и способы ее получения | |
| PH12022500004A1 (en) | Il-15 conjugates and uses thereof | |
| PE20211473A1 (es) | Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso | |
| AR061598A1 (es) | Nitroderivados heterociclicos como antagonistas de receptor de endotelina | |
| Zhao et al. | Heterocyclic molecules tethered branched polymers with innate immune stimulating activity | |
| EA201190315A1 (ru) | ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ПАКЛИТАКСЕЛЯ И ДОЦЕТАКСЕЛЯ С КОНТРОЛИРУЕМЫМ ПОД ДЕЙСТВИЕМ pH ВЫСВОБОЖДЕНИЕМ КАНЦЕРОСТАТИЧЕСКОГО АГЕНТА | |
| EA202190298A1 (ru) | Циклические динуклеотиды в качестве агонистов sting | |
| US20110262492A1 (en) | Catalyst and byproduct-free native chemical ligation using cyclic thioester precursors | |
| AR115677A1 (es) | Composición de base acuoso con reticulación química | |
| CL2023001294A1 (es) | Dominio de unión a antígeno con tasa de recorte reducida | |
| AR030458A1 (es) | Procedimiento para la fabricacion de un inmunogeno de vacuna conjugado, conjugado obtenido mediante el mismo, uso del conjugado para la fabricacion de un medicamento y composicion de vacuna que comprende dicho conjugado | |
| AR113980A1 (es) | Método para mejorar la biodisponibilidad oral de una droga |